Continued participation in a ten-year tight control treat-to-target study in rheumatoid arthritis: why keep patients doing their best?

Arthritis Care Res (Hoboken). 2015 May;67(6):739-45. doi: 10.1002/acr.22540.

Abstract

Objective: To identify risk factors for early study termination and motivators for adherence to a long-term followup trial and to improve completeness of long-term studies.

Methods: Risk factors for early termination in 508 included patients were identified through Cox regression analysis. Patients completing the 10-year followup filled in a questionnaire on possible motives for continued study participation.

Results: Risk factors for early termination were higher age (hazard ratio [HR] 1.03, 95% confidence interval [95% CI] 1.02-1.04), functional disability during the preceding year (HR 1.54, 95% CI 1.20-1.99), having achieved drug-free remission (HR 6.62, 95% CI 2.07-21.14), limited joint damage (HR 0.98, 95% CI 0.97-0.995 for actual damage; HR 0.83, 95% CI 0.73-0.94 for damage progression), and few adverse events (HR 0.35, 95% CI 0.26-0.47). A total of 288 of 313 patients (92%) attending the last visit answered the questionnaire. The majority mentioned contributing to scientific research (97% agreed), helping other patients (91%), and learning about new treatment strategies (84%) and their disease (85%) as reasons to continue participation. Next, patients mentioned tight control (202 of 278 patients), good treatment strategy (128 of 278), good medication (117 of 278), and good half-term results (102 of 278) as motivators. More than 95% of patients experienced participation "as expected" or "better than expected." Additional examinations during yearly visits (extra questionnaires, imaging) were mentioned as "worse than expected" (10%), as was answering routine questionnaires (7%).

Conclusion: Continued participation was relatively high in the Treatment Strategies for Rheumatoid Arthritis (BeSt) Study. Higher age, functional disability, drug-free remission, little joint damage, and few adverse events predicted early study termination. Main motives for continued participation were a willingness to contribute to research, help future patients, and because patients had good experiences with the study protocol.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Aged
  • Aged, 80 and over
  • Antirheumatic Agents / adverse effects
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / diagnosis
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / psychology
  • Disability Evaluation
  • Disease Progression
  • Female
  • Health Knowledge, Attitudes, Practice
  • Humans
  • Male
  • Medication Adherence*
  • Middle Aged
  • Motivation
  • Netherlands
  • Patient Dropouts
  • Patients / psychology*
  • Proportional Hazards Models
  • Remission Induction
  • Risk Factors
  • Severity of Illness Index
  • Single-Blind Method
  • Surveys and Questionnaires
  • Time Factors
  • Treatment Outcome

Substances

  • Antirheumatic Agents

Associated data

  • NTR/NTR262
  • NTR/NTR265